Effective February 2023, the California Department of Public Health (CDPH) added the following antipsychotic injectables to the ADAP formulary: Aripiprazole (Abilify Maintena®), Aripiprazole (Aristada®), Olanzapine (Zyprexa Relprevv™), Paliperidone (Invega Sustenna®), Risperidone (Risperdal Consta®). The addition of these medications provides options to ensure that ADAP clients receive care consistent with current national guidelines to manage severe depression, schizophrenia, and schizoaffective disorder among people with HIV. Please see link to the CDPH management memo released for more information: ADAP MM 2023-02. More information on ADAP which helps ensure that people living with HIV in California, who are uninsured or under-insured, have access to medication can be found here (hyperlink to https://www.cdph.ca.gov/Programs/CID/DOA/Pages/OAadap.aspx).
Also, at the federal level, please be aware that Medicare is making plans to expand coverage of Alzheimer’s drugs.